News

Adheron has developed a new technology that disrupts immune cell adhesion through Cadherin-11 (Cad-11), a cell surface protein, to develop potential treatments for various inflammatory and autoimmune diseases.

Being conducted in Sierra Leone’s Kambia district, the EBOVAC-Salone study tests a regimen consisting of two vaccine components based on AdVac technology from Crucell Holland, one of the

LAMP-vax is a next-generation DNA vaccine which can stimulate an immune response against a particular protein, injecting the DNA encoding the protein rather than the protein itself. The

The OLE trial is designed to evaluate the long-term safety and efficacy of ALN-AT3 and provide continued dosing for people with hemophilia enrolled in the Phase I study.

The designation is based on data from the breast cancer cohort expansion of the company’s Phase I trial, which studied the efficacy and safety of abemaciclib, a cyclin-dependent

The new formulation of Copaxone is anticipated to allow for a less frequent dosing regimen for patients with RRMS in the country. Teva Global Specialty Medicines president and

Under the deal, Lonza will develop a scalable manufacturing process for Benitec’s ddRNAi-based and Adeno-Associated Virus (AAV)-delivered products specified for therapeutic use in humans. Lonza will use its

In September, FDA had granted orphan drug designation for avelumab, to treat MCC, a rare and aggressive type of skin cancer. Pfizer oncology chief medical officer and clinical

Riociguat, a soluble guanylate cyclase (sGC) stimulator, has been approved since 2013 for the treatment of adults suffering from this life-threatening disorder of the lungs. The development and